Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF 77 Capex-to-Operating-Cash-Flow is 0.09 as of Dec. 2025, which is 50% above its 10-year median of 0.06. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.23 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 440 Medical Devices & Instruments companies, NIOX Group ranks better than 92.95% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
NIOX Group (OTCPK:CSSPF) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
NIOX Group Capex-to-Operating-Cash-Flow Related Terms
NIOX Group Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for NIOX Group's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSSPF vs ABT, SYK, MDT: Capex-to-Operating-Cash-Flow Comparison
For the Medical Devices subindustry, NIOX Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Capex-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where NIOX Group's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.09 mean?
NIOX Group (CSSPF) has a Capex-to-Operating-Cash-Flow of 0.09 as of Dec. 2025. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on NIOX Group and its competitors. This is 50% above median its historical median of 0.06. Over the past decade, NIOX Group's Capex-to-Operating-Cash-Flow has ranged from 0.02 to 0.14. According to the industry distribution chart, NIOX Group ranks #31 out of 440 companies in the Medical Devices & Instruments industry, placing it in the top 7%.
Is NIOX Group's Capex-to-Operating-Cash-Flow too high?
NIOX Group's current Capex-to-Operating-Cash-Flow of 0.09 is 50% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.14. The Medical Devices & Instruments industry median Capex-to-Operating-Cash-Flow is 0.41. NIOX Group's value of 0.09 is 78% below this industry median. Based on the distribution chart, NIOX Group ranks #31 out of 440 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Capex-to-Operating-Cash-Flow compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #31 out of 440 companies for Capex-to-Operating-Cash-Flow. This places NIOX Group in the top 7% of its industry — outperforming the majority of peers. The industry median Capex-to-Operating-Cash-Flow is 0.41. NIOX Group's value of 0.09 is 78% below this benchmark. Historically, NIOX Group's own Capex-to-Operating-Cash-Flow has ranged from 0.02 to 0.14 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.41, NIOX Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Medical Devices & Instruments company?
The median Capex-to-Operating-Cash-Flow among Medical Devices & Instruments companies is 0.41, based on 440 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Capex-to-Operating-Cash-Flow of 0.09 is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Capex-to-Operating-Cash-Flow is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Capex-to-Operating-Cash-Flow is 0.09, which is 50% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.23, compared to a current price of $0.82 — trading 33.3% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.09, which is 50% above median its 10-year median of 0.06 and 78% below the Medical Devices & Instruments industry median of 0.41. NIOX Group's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Capex-to-Operating-Cash-Flow is 0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.82 is trading 33.3% below its estimated GF Value™ of $1.23.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Capex-to-Operating-Cash-Flow: 0.09 (50% above median its 10-year median of 0.06)
GF Value™: $1.23 vs. price of $0.82 (33.3% below fair value)
Industry Position: 78% below the Medical Devices & Instruments median (#31 of 440)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
